{"id":13055,"date":"2024-11-19T20:04:35","date_gmt":"2024-11-19T13:04:35","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=13055"},"modified":"2024-11-19T20:04:35","modified_gmt":"2024-11-19T13:04:35","slug":"brii-bio-delivers-first-head-to-head-comparison-of-sirna-elebsiran-and-peg-ifn%ce%b1-combination-versus-peg-ifn%ce%b1-alone-at-aaslds-the-liver-meeting-2024-demonstrating-higher-loss-of-hbv","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=13055","title":{"rendered":"Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFN\u03b1 Combination versus PEG-IFN\u03b1 Alone at AASLD’s The Liver Meeting\u00ae 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

48-week end-of-treatment data from the\u00a0ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFN\u03b1<\/i><\/p>\n

Data from multiple combination studies sponsored by the Company and its\u00a0partner continue to support the Company’s strategy of HBV functional cure in broader patient populations with the right combination regimens<\/i><\/p>\n

DURHAM, N.C.<\/span> and BEIJING<\/span><\/span>, Nov. 19, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0Brii Biosciences Limited<\/a> (“Brii Bio<\/span>,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae<\/sup>, taking place from November 15 – 19<\/span> in San Diego, CA.<\/span><\/p>\n

\n<\/div>\n

ENSURE is an active-controlled and randomized Phase 2 study designed to evaluate the contribution of elebsiran (BRII-835, VIR-2218), an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFN\u03b1)\u00a0in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU\/mL. The study excluded HBV patients with low baseline HBsAg levels (<100 IU\/mL) to investigate the potential curative benefits in broader patient populations. The ENSURE 48-week end-of-treatment (EOT) data demonstrated that 26.3% (5\/19) or 33.3% (6\/18) of participants receiving 200 mg or 100 mg elebsiran in combination with PEG-IFN\u03b1 versus 5.6% (1\/18) receiving PEG-IFN\u03b1 alone achieved HBsAg seroclearance at EOT.\u00a0<\/p>\n

“The EOT data from the ENSURE study are clearcut,” said Dr. Jidong Jia<\/span>, Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China<\/span>. “Previous studies have shown that combination of siRNA and PEG-IFN\u03b1 is one of the most promising therapies to achieve higher HBsAg seroclearance. The ENSURE study marks the first evidence to delineate the contribution of siRNA towards functional cure on top of the well-established PEG-IFN\u03b1\u00a0therapy. I believe that elebsiran has the potential to make a substantial impact in the pursuit of higher HBV functional cure rates.”<\/p>\n

“We are encouraged that the data from this trial continue to support our goal of developing\u00a0a functional cure for chronic HBV\u00a0in target populations,” said David Margolis<\/span>, MD, Chief Medical Officer of Brii Bio<\/span>.\u00a0“The results highlight the potential of elebsiran as\u00a0the backbone of combination treatment regimens currently being evaluated in several ongoing trials. We look forward to advancing elebsiran through our ongoing Phase 2 studies in combination with other modalities, aiming to deliver higher functional cure rates to 254\u00a0million patients worldwide living with chronic HBV infection.”<\/p>\n

Abstract Number: <\/b>5008<\/p>\n

Late-Breaking Oral Presentation Title: <\/b>Efficacy and safety of elebsiran (BRII-835) and pegylated interferon alpha (PEG-IFN\u03b1) combination therapy vs PEG-IFN\u03b1 in virologically suppressed participants with chronic hepatitis B virus (HBV) infection: preliminary results<\/p>\n

Presenter:<\/b>\u00a0Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China<\/span><\/p>\n